A genomics software company moving polygenic risk scores out of the research lab and into routine, equitable clinical care.
A cholesterol test tells you about today. Your genome held the same warning decades earlier - it just needed something to read it. Allelica builds that reader.
Founded in Rome in 2018 by three scientists who count among the field's leading polygenic risk score researchers - Giordano Bottà, Paolo Di Domenico, and George Busby - Allelica set out to close a stubborn gap in genomics. The science of polygenic risk scoring, which combines the small effects of many genetic variants into a single estimate of inherited disease susceptibility, had matured across twenty years of research. What was missing was the unglamorous part: reliable, validated software a hospital could actually run, and scores that worked for patients of every ancestry rather than mainly those of European descent.
Today the company sells a cloud platform to labs and health systems, provides clinical-grade genetic tests, and licenses its underlying engine - Illumina, one of the giants of genomics, is among the licensees. In January 2026, its multi-ancestry coronary artery disease study was cited in the ACC/AHA cardiovascular prevention guidelines, a signal that genetic risk is beginning to shape how cardiologists treat real patients.
Allelica is deliberately small - roughly eleven people - yet its software reaches large clinical and genomics enterprises. That contrast is the whole point of the business: in genomics, the moat isn't headcount, it's whether the science holds up when clinicians actually use it.
Single-gene tests look for one broken part. A polygenic risk score reads thousands of common variants across the whole genome and adds up their tiny effects into one number - an estimate of how much inherited risk a person carries for a given disease.
Builds new scores by running four state-of-the-art algorithms in parallel to find the model that best predicts a given disease.
Tests whether a score holds up across different genetic ancestries - the step most PRS pipelines skip, and where accuracy usually breaks.
Applies the validated score to an individual patient's data and returns a clinical-grade risk estimate a physician can use.
The AbsoluteDx test layers one more idea on top: it reports rare, high-impact mutations (monogenic risk) alongside the genome-wide polygenic score - because a patient doesn't care which category their risk falls into, they just want to know whether to worry.
Most polygenic risk scores were trained on databases that are overwhelmingly of European ancestry, so they predict far less accurately for everyone else. Allelica made multi-ancestry validation a core part of its platform rather than an afterthought, and at ASHG 2024 introduced its “8 billion method” for modeling human genetic diversity without ancestry labels - a step toward risk scores that work for the whole population.
Bars illustrate qualitative emphasis drawn from public statements and press releases, not precise metrics.
Allelica's priority was to develop a polygenic risk score that can benefit everyone, regardless of their ancestries - not just populations of European descent. — Paraphrased from Allelica public statements & press
The DISCOVER / VALIDATE / PREDICT cloud workflow that takes a polygenic risk score from raw genotypes through multi-ancestry validation to a clinical prediction.
A clinical-grade laboratory-developed test for coronary artery disease, breast cancer, prostate cancer, Type 2 diabetes, and Alzheimer's disease.
A single test combining monogenic (rare-variant) and polygenic risk, capturing the interplay between rare pathogenic mutations and genome-wide inherited risk.
A technique for modeling human genetic diversity without ancestry labels, improving PRS performance across diverse populations and reducing bias.
Allelica runs a B2B model with two engines. It licenses its PRS software to genomics companies and labs - Illumina is a public example - and it provides clinical-grade PRS and LDT testing to health systems and academic medical centers such as Baylor College of Medicine. Research and pharmaceutical collaborations round out the mix.
Health systems, academic medical centers, clinical and reference laboratories, genomics companies, and pharma research groups. Named users and collaborators include Baylor College of Medicine, Labcorp, and Illumina - a small team selling into some of the largest players in the field.
Allelica has raised roughly $3.4M in total. Its defining round was a $1.75M seed in March 2021, led by Valor Ventures, which coincided with the company relocating its headquarters to the United States.
Three PRS scientists set out to translate polygenic risk research into clinical tools.
DISCOVER, VALIDATE, and PREDICT modules built for developing and applying scores across ancestries.
Seed round led by Valor Ventures; headquarters relocates to the United States.
Ancestry-specific LDT covering heart disease, breast and prostate cancer, diabetes, and Alzheimer's.
Clinical deployment with Baylor; AbsoluteDx combines monogenic and polygenic risk; “8 billion method” debuts at ASHG.
Multi-ancestry CAD score cited in the ACC/AHA cardiovascular prevention guidelines.
Allelica sits at the point where genomics research meets clinical delivery. The alternatives to its platform are companies like Genomics plc, Fabric Genomics, Color Health, and Nucleus Genomics, along with academic PRS pipelines and the in-house bioinformatics teams of large labs. Its distinguishing bets are two: making multi-ancestry validation a first-class feature rather than a caveat, and packaging rare-variant and polygenic risk together in a single clinical report. In a field crowded with research-grade tools, Allelica's wager is that the winning product is the one clinicians can actually trust and run.
The paired l's in the Allelica wordmark are stylized as a chromosome.
Founded in Italy, the company moved its headquarters stateside alongside its 2021 seed round.
With ~11 employees, its software still ended up licensed by Illumina.
The “8 billion method” is named for Earth's population - a score should work for everyone.
Its founders are counted among the world's leading polygenic risk score researchers.
Its research reached the ACC/AHA guidelines - where science turns into clinical practice.
Allelica is a genomics software company that develops polygenic risk score (PRS) technology and clinical tests, helping labs and health systems predict a person's genetic risk for common diseases such as heart disease and cancer - across multiple ancestries.
It aggregates the effects of many genetic variants across the genome into a single number estimating inherited susceptibility to a disease. Unlike single-gene tests, it captures genome-wide risk.
It was founded around 2018 in Rome by Giordano Bottà (CEO), Paolo Di Domenico, and George Busby, who are among the leading scientists in polygenic risk scoring.
It focuses on multi-ancestry PRS - scores validated to work across diverse populations rather than mainly European genomes - and combines monogenic and polygenic risk in a single clinical test, AbsoluteDx.
Health systems, academic medical centers, and labs - including Baylor College of Medicine and Labcorp - along with genomics companies such as Illumina, which licensed Allelica's PRS software.
Profile compiled from public sources including allelica.com, GenomeWeb, PR Newswire, Business Wire, Crunchbase, and peer-reviewed literature. Figures are approximate where noted.